Hydantoin derivative compounds, methods of use and methods of treatment
The present disclosure provides compositions including a hydantoin derivative compound, pharmaceutical compositions including a hydantoin derivative compound, methods of treatment of a condition (e.g., bacterial infection) or disease, methods of treatment using compositions or pharmaceutical compositions, and the like.
1. A hydantoin derivative compound having the following structure:
wherein D 1 is a hydantoin core, D 2 is a membrane interacting domain, R 1 is a hydrophobic group, R 2 is selected from the group consisting of a NH 2 group, an aminobutyl group, an aminopentyl group, an aminohexyl group, and an aminopropyl group, and X is a lipid tail.
2. The hydantoin derivative compound of claim 1 , wherein the lipid tail X is a 5 to 15 carbon alkyl group.
3. The hydantoin derivative compound of claim 2 , wherein the lipid tail X is selected from a 10 to 12 carbon linear alkyl group.
4. The hydantoin derivative compound of claim 2 , wherein R 1 is an alkyl group, aryl group, or a cycloalkyl group, each of which is substituted or unsubstituted.
5. The hydantoin derivative compound of claim 4 , wherein R 1 is an ethyl group, a phenyl group, meta-chlorobenzyl, indole, biphenyl, terphenyl, or 6-chloro indole.
6. The hydantoin derivative compound of claim 2 , wherein the hydantoin derivative compound has the following structure:
7. A pharmaceutical composition comprising:
a hydantoin derivative compound, or a pharmaceutically acceptable salt of the hydantoin derivative compound, having the following structure:
wherein D 1 is a hydantoin core, D 2 is a membrane interacting domain, R 1 is a hydrophobic group, R 2 is selected from the group consisting of a NH 2 group, an aminobutyl group, an aminopentyl group, an aminohexyl group, and an aminopropyl group, and X is a lipid tail;
and a pharmaceutically acceptable carrier.
8. The pharmaceutical composition of claim 7 , wherein the lipid tail X is a 5 to 15 carbon alkyl group.
9. The pharmaceutical composition of claim 7 , wherein the lipid tail X is selected from a 10 to 12 carbon linear alkyl group.
10. The pharmaceutical composition of claim 7 , wherein R 1 is an alkyl group, aryl group, or a cycloalkyl group, each of which is substituted or unsubstituted.
11. The pharmaceutical composition of claim 10 , wherein R 1 is an ethyl group, a phenyl group, meta-chlorobenzyl, indole, biphenyl, terphenyl, or 6-chloro indole.
12. The pharmaceutical composition of claim 7 , wherein the hydantoin derivative compound has the following structure: